We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalABMD - Replacement Heart System

Previous 10 Next 10 
From: Lynn9/14/2018 9:13:20 PM
1 Recommendation   of 147
7 Tech Stocks Sporting Amazon-Like Growth

Louis Navellier
September 13, 2018

[Only ABMD section copied/pasted]

Tech Stocks to Buy: Abiomed, Inc. (ABMD)

View photos

Tech Stocks to Buy: Abiomed, Inc. (ABMD)

Abiomed, Inc. (NASDAQ: ABMD) makes specific medical devices that assist or replace the pumping function of a failing heart.

What makes ABMD’s devices unique is, implanting them is a relatively easy process, so significant costs or energy isn’t necessary up front.

For example, if someone comes into the Emergency Room with a heart attack, the team can put in an Impella Heart Pump and then, once the patient is stable, figure out what the next steps will be.

And its products are seeing very good results. In late October ABMD reported its FYQ2 numbers; revenue was up 29% and patient utilization was up by 33%.

Those are very big numbers and bode well for Impella’s future, especially because it packs a lot of bang for the buck, which makes health insurance companies very happy.

Up 104% YTD, ABMD is just starting its run.

Share RecommendKeepReplyMark as Last Read

To: High-Tech East who wrote (106)9/14/2018 11:47:16 PM
From: Lynn
   of 147
You haven't been around since 2005, Ken, hope you are fine. Looking back at past postings, this comment you made to Charles [when ABMD looked like it might be a candidate for Chapter 11] made me sigh:

... I am hanging in there indefinitely on Abiomed - I guess the same way lots of people are with Sun ...
SUNW... Talk about a climb into the stratosphere than about-face to the almost ground when ORCL snatched it--for cash rather than stock (groan). I still think about some people on that thread who could not believe it would continue to decline and actually bought more shares when it was in the 90s. Should ABMD start pulling a, "SUNW," I sure hope I am smart enough to bail! SUNW... I could cry. :(

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Lynn who wrote (136)9/24/2018 12:20:51 PM
From: dominoe
   of 147
Dont look now but we are soaring on positive news of our impact on lowering mortality and morbidity for certain cardiac ailment.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

From: Julius Wong9/24/2018 2:57:39 PM
1 Recommendation   of 147
Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival

Share RecommendKeepReplyMark as Last Read

To: dominoe who wrote (137)9/24/2018 6:11:19 PM
From: Lynn
   of 147
Hey, thank you, dominoe. I have been a tad bit gloomy over a few stocks I recently (past 6 months) picked up. I needed this positive ABMD news/move!


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Lynn who wrote (139)9/25/2018 12:07:17 PM
From: dominoe
   of 147
Then you must be feeling great between yesterday and today.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: dominoe who wrote (140)9/25/2018 12:17:31 PM
From: Lynn
   of 147
:) :) Without looking how my make-me-groan stocks are doing, just reading your reply to me--which made my notebook 'ding,' seeing ABMD is up 6%--YES!! A ray of sunshine. Thanks, dominoe.

S&P 500 Movers: [worst performer removed], ABMDIn early trading on Tuesday, shares of ABIOMED (NASDAQ: ABMD) topped the list of the day's best performing components of the S&P 500 index, trading up 4.4%. Year to date, ABIOMED registers a 133.7% gain.

[snip to end]

You are right, Go ABMD!!

Share RecommendKeepReplyMark as Last Read

From: Lynn9/28/2018 10:10:39 PM
   of 147
World's Smallest Heart Pump Fuels Red-Hot Medtech Stock By
Bailey Lipschultz

September 27, 2018, 7:30 AM EDT Updated on September 27, 2018, 10:37 AM EDT

Abiomed has more than doubled this year as revenue skyrockets

Patents and technology keep potential competitors at bay
It may be hard to justify buying a company that nearly tripled over the past 12 months, but then there’s Abiomed Inc.

With annual sales growth seen at more than 25 percent through 2021, the maker of the world’s smallest heart pump has quickened the pulse of investors, analysts and -- not surprisingly -- its chief executive.

Abiomed Impella

Source: Abiomed
“We’re just getting started,” Michael Minogue, president and CEO, said in an interview at the company’s headquarters earlier this month. Abiomed has spent more than $200 million over the last 10 years developing and improving its Impella devices, he said.

Abiomed’s hot run can be at least partially attributed to the patented technology that provides an almost impenetrable barrier from competitors seeking involvement in the segment. Plus, it has space in the market to grow. The Danvers, Massachusetts-based company estimates it has only reached about a tenth of its addressable market, with more products and patents on the horizon. On top of that, there’s global expansion.

Abiomed’s preparing for a rush. Its recently expanded facilities in Danvers and Aachen, Germany can now produce more than $1 billion in product a year. That compares to fiscal first quarter sales of $180 million, according to data compiled by Bloomberg.

The minimally invasive Impella devices can be inserted via a standard catherization procedure and allow patients to maintain their native heart instead of more invasive surgeries that may require a heart transplant. The tiny pump is slightly less than 5 millimeters in diameter compared to other devices that are more than double the size.

Of course, the rally that’s made it one of the Standard & Poor 500 Index’s hottest stocks this year may also give new investors pause. Shares opened higher on Thursday to extend what was an eight session rally, the longest winning streak in four years, before reversing gains.

Not a Bargain“If there’s one constraint on the company it is the valuation,” Jefferies analyst Raj Denhoy said in a phone interview. “It’s the most expensive stock that we track in medical devices and by a good amount, frankly. But again, it’d be hard to find another company with the characteristics as this company in terms of a sustainable growth story.”

Rapid adoption of Abiomed’s Impella technology, increased appreciation for the company’s competitive moats and pipeline optionality explain the company’s nearly two-year stock surge, according to BNP Paribas portfolio manager Jon Stephenson. And he sees more upside to come.

“A lot of people look at the valuation as mind-boggling, but in Abiomed’s case, the addressable market for the indications in which they’ve already launched are huge,” Stephenson, who helps oversee $450 million in BNP’s World Health Care fund, said by telephone. The company has 321 patents protecting its technology with an additional 338 pending, management noted.

Not to say that Abiomed’s completely protected from rivals. Abbott Laboratories’ HeartMate PHP is a device currently being studied to take on the Impella and its incarnations. That said, early results from a study underwhelmed analysts at the Transcatheter Cardiovascular Therapeutics meeting in San Diego over the weekend.

The updates showed Abiomed “will be without meaningful competition to Impella for several more years at least,” Jefferies’ Denhoy wrote in a note to clients. In the interim, there’s plenty of demand. The company has five approved pumps that qualify for reimbursement from the Centers for Medicare and Medicaid Services and major insurers, CEO Minogue said. The device maker could bring three more products to market over the next few years that could lead to increased adoption.

Current indications conservatively show a market potential of close to 200,000 to 300,000 cases in the U.S., Denhoy said. A successful trial could add “another couple hundred thousand patients,” he said.

The next key catalyst for investors, outside of second-quarter results expected in late October, will be the highly-anticipated presentation of its 50-patient STEMI door-to-unloading safety and feasibility study in November.

— With assistance by Javon Thompson

(Updates with details on the pump in the sixth paragraph, shares in seventh paragraph.)

Share RecommendKeepReplyMark as Last Read

From: Julius Wong10/29/2018 7:53:36 AM
   of 147
ABMD: Analyst Ratings & Price Targets

Share RecommendKeepReplyMark as Last Read

From: tech1019/12/2019 4:51:23 PM
   of 147
If You Like EPS Growth Then Check Out Abiomed (NASDAQ:ABMD) Before It's Too Late

Simply Wall St

Simply Wall St.September 9, 2019

View photos

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling short, can easily find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.'

So if you're like me, you might be more interested in profitable, growing companies, like Abiomed ( NASDAQ:ABMD). While profit is not necessarily a social good, it's easy to admire a business than can consistently produce it. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.

Check out our latest analysis for Abiomed

How Fast Is Abiomed Growing Its Earnings Per Share?In the last three years Abiomed's earnings per share took off like a rocket; fast, and from a low base. So the actual rate of growth doesn't tell us much. As a result, I'll zoom in on growth over the last year, instead. Like a wedge-tailed eagle on the wind, Abiomed's EPS soared from US$3.72 to US$5.72, in just one year. That's a commendable gain of 54%.

I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). The good news is that Abiomed is growing revenues, and EBIT margins improved by 3.1 percentage points to 30%, over the last year. Ticking those two boxes is a good sign of growth, in my book.

In the chart below, you can see how the company has grown earnings, and revenue, over time. Click on the chart to see the exact numbers.

NasdaqGS:ABMD Income Statement, September 9th 2019

In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of Abiomed's forecast profits?

Are Abiomed Insiders Aligned With All Shareholders?Since Abiomed has a market capitalization of US$8.6b, we wouldn't expect insiders to hold a large percentage of shares. But we do take comfort from the fact that they are investors in the company. Indeed, they have a glittering mountain of wealth invested in it, currently valued at US$179m. This suggests to me that leadership will be very mindful of shareholders' interests when making decisions!

Should You Add Abiomed To Your Watchlist?You can't deny that Abiomed has grown its earnings per share at a very impressive rate. That's attractive. Further, the high level of insider buying impresses me, and suggests that I'm not the only one who appreciates the EPS growth. So this is very likely the kind of business that I like to spend time researching, with a view to discerning its true value. Now, you could try to make up your mind on Abiomed by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.

Although Abiomed certainly looks good to me, I would like it more if insiders were buying up shares. If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10